Background And Aim: Endoscopic submucosal excavation (ESE) is commonly used to treat gastrointestinal stromal tumors (GISTs), especially for tumor sizes within 2 cm; compared with the conventical ESE, the efficacy and safety of the no-submucosal injection (NSI) ESE remains unclear. The aim of this study was to assess the clinical efficacy and safety of NSI-ESE for gastric stromal tumors.
Methods: ESE was performed in 102 patients at our hospital between January 2018 and January 2020, and the clinical features, surgical outcomes, complications, cost of performance, pathological diagnosis, and risk classification were evaluated.
Results: All tumors were completely resected by endoscopic resection (ER), with a complete resection rate of 100%. It was achieved by ESE/EFTR (endoscopic full-thickness resection) in 49 cases with submucosal injection, and by ESE/EFTR in 53 cases with NSI-ESE. The mean surgical time in cases with submucosal injection was 25.86 ± 4.45 min, compared to the cases without submucosal injection (17.23 ± 3.47 min), and the difference was significant ( < 0.001); the exposure time of tumor, the time of complete excavation of tumor, procedure cost, and hospital stay in the NSI-ESE group were all lower than those cases with submucosal injection ( < 0.05). In the risk classification, 95 (93.1%) cases had a very low risk, 4 (4.0%) cases had a low risk, and 2 (2.0%) cases had a high risk. No recurrence or metastasis was observed during the follow-up period of 18 ± 6 months (range: 13-25 months).
Conclusions: NSI-ESE is a feasible, effective, and safe treatment for gastric GISTs; compared to the conventional ESE, NSI-ESE has the following advantages: it decreases procedure time, it lowers the risk of perforation, and it is cost-effective.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9013937 | PMC |
| http://dx.doi.org/10.3389/fonc.2022.792445 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Histological prediction and choice of the best resection strategy in front of a colorectal lesion > 2 cm: prospective comparison of endoscopic characterization, non-targeted and targeted biopsies.
Surg Endosc
January 2025
Department of Gastroenterology and Endoscopy, Edouard Herriot Hospital, 69437, Lyon, France.
Background: Accurate endoscopic characterization of colorectal lesions is essential to predict histology and select the best treatment strategy but remains very difficult. Instead of the recommended endoscopic characterization, many gastroenterologists routinely perform biopsies of the lesion to propose endoscopic resection with or without R0 intent. The aim of this study was to determine which of endoscopic characterization or biopsies, either targeted (TB) or non-targeted (NTB), is the most effective to determine the best treatment strategy for colorectal neoplasia > 2 cm.
View Article and Find Full Text PDFClinical and Pathological Analysis of Perianal Paget's Disease: A Case Report and Review of 89 Cases.
Cancer Diagn Progn
January 2025
Department of Gastroenterological Surgery, Osaka International Medical and Science Center, Osaka Keisatsu Hospital, Osaka, Japan.
Background/aim: Perianal Paget's disease (PPD) is an intraepithelial invasion of the perianal skin that is frequently associated with anorectal carcinoma. Rectal canal carcinoma with Pagetoid spread (PS) is a relatively rare disease, and few reports on its outcomes are available. The relatively rare nature of this disease makes the development of treatment recommendations difficult.
View Article and Find Full Text PDFA newly developed articulated through-the-scope traction device, TRACMOTION, has been used clinically for endoscopic submucosal dissection (ESD). However, there are few reports on the characteristics of this device and the lesion types for which it is most effective. Therefore, we evaluated its optimal use, efficacy, and safety clinically in animals.
View Article and Find Full Text PDFAbdominal lymphangioleiomyomatosis in a man presenting with gastrointestinal hemorrhage as the first manifestation: a case report.
Front Med (Lausanne)
December 2024
Department of Gastroenterology, The First Affiliated Hospital of Dali University, Dali, Yunnan, China.
Lymphangioleiomyomatosis (LAM) is a rare, low-grade malignant condition that typically affects women of childbearing age and primarily involves the lungs. While cases involving males and affecting the gastrointestinal tract are exceedingly uncommon. This report discusses an unusual case of abdominal LAM in a male patient with gastrointestinal hemorrhage.
View Article and Find Full Text PDFLow-dose Imatinib Efficacy in a Gastrointestinal Stromal Tumor Patient With Exon 11 W557_K558 Deletion.
In Vivo
December 2024
Department of Medical Oncology, Hyogo Cancer Center, Akashi, Japan.
Article Synopsis
- Gastrointestinal stromal tumors (GISTs) are rare cancers linked to mutations in the c-KIT gene, with one common mutation being a deletion in exon 11, as seen in an 82-year-old male patient diagnosed in June 2023.
- The patient subsequently received a low-dose imatinib treatment protocol, starting at 400 mg/day and tapering down to 200 mg/day, which resulted in a reduction of the tumor size over several months.
- The study suggests that low-dose imatinib can be an effective treatment option for GIST patients with the W557_K558 deletion, especially for those who cannot tolerate higher doses.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!